ChimeriVax-West Nile virus live-attenuated vaccine: Preclinical evaluation of safety, immunogenicity, and efficacy

被引:156
作者
Arroyo, J
Miller, C
Catalan, J
Myers, GA
Ratterree, MS
Trent, DW
Monath, TP
机构
[1] Acambis Inc, Cambridge, MA 02139 USA
[2] DynPort Vaccine Co, LLC, Frederick, MD USA
[3] Tulane Natl Primate Res Ctr, Covington, LA USA
[4] Vaxin Inc, Birmingham, AL USA
关键词
D O I
10.1128/JVI.78.22.12497-12507.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected in North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live-attenuated vaccine developed with this technology has successfully undergone phase I and 11 clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstructural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WNO2 vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.
引用
收藏
页码:12497 / 12507
页数:11
相关论文
共 38 条
  • [1] Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E
    Allison, SL
    Stiasny, K
    Stadler, K
    Mandl, CW
    Heinz, FX
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (07) : 5605 - 5612
  • [2] Mutational evidence for an internal fusion peptide in flavivirus envelope protein E
    Allison, SL
    Schalich, J
    Stiasny, K
    Mandl, CW
    Heinz, FX
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (09) : 4268 - 4275
  • [3] Yellow fever vector live-virus vaccines: West Nile virus vaccine development
    Arroyo, J
    Miller, CA
    Catalan, J
    Monath, TP
    [J]. TRENDS IN MOLECULAR MEDICINE, 2001, 7 (08) : 350 - 354
  • [4] Molecular basis for attenuation of neurovirulence of a yellow fever virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE)
    Arroyo, J
    Guirakhoo, F
    Fenner, S
    Zhang, ZX
    Monath, TP
    Chambers, TJ
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (02) : 934 - 942
  • [5] Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype
    Beasley, DWC
    Li, L
    Suderman, MT
    Barrett, ADT
    [J]. VIROLOGY, 2002, 296 (01) : 17 - 23
  • [6] Butrapet Siritorn, 2002, Southeast Asian Journal of Tropical Medicine and Public Health, V33, P589
  • [7] *CENT DIS CONT PRE, 1999, MMWR-MORBID MORTAL W, V48, P845
  • [8] *CENT DIS CONT PRE, 2003, W NILE VIRUS ACTIVIT, V52, P1022
  • [9] Yellow fever Japanese encephalitis chimeric viruses: Construction and biological properties
    Chambers, TJ
    Nestorowicz, A
    Mason, PW
    Rice, CM
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (04) : 3095 - 3101
  • [10] Neuroadapted yellow fever virus 17D: Genetic and biological characterization of a highly mouse-neurovirulent virus and its infectious molecular clone
    Chambers, TJ
    Nickells, M
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (22) : 10912 - 10922